Transarterial Chemoembolization Plus Sorafenib versus Transarterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses and Systematic Reviews

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Yan J, Deng M, Kong S, et al. Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: a mini review. iLIVER. 2022;1(4):225–234. doi:10.1016/j.iliver.2022.10.001
   Google Scholar
• Yan J, Deng M, Li T, et al. Efficacy and complications of transarterial chemoembolization alone or in combination with different protocols for hepatocellular carcinoma: a Bayesian network meta-analysis of randomized controlled trials. iLIVER. 2023;2(2):130–141. doi:10.1016/j.iliver.2023.03.002
   Google Scholar
• Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49(3):851–859. doi:10.1002/hep.22734
   PubMed Web of Science ®Google Scholar
• Chen F, Zhang W, Gao X, Yuan H, Liu K. The role of small interfering RNAs in hepatocellular carcinoma. J Gastrointest Cancer. 2023. doi:10.1007/s12029-023-00911-w
   Web of Science ®Google Scholar
• Radosevic A, Quesada R, Serlavos C, et al. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled Phase 2 trial. Sci Rep. 2022;12(1):316. doi:10.1038/s41598-021-03802-x
   PubMedGoogle Scholar
• Criss CR, Makary MS. Salvage locoregional therapies for recurrent hepatocellular carcinoma. World J Gastroenterol. 2023;29(3):413–424. doi:10.3748/wjg.v29.i3.413
   PubMed Web of Science ®Google Scholar
• Shen J, Qi W, Dai J, et al. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy. Chin Med J. 2021;135(3):301–308. doi:10.1097/CM9.0000000000001864
   PubMed Web of Science ®Google Scholar
• Su GL, Altayar O, O’Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162(3):920–934. doi:10.1053/j.gastro.2021.12.276
   PubMed Web of Science ®Google Scholar
• Shitara K, Di Bartolomeo M, Mandala M, et al. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. J Immunother Cancer. 2023;11(6):e006920. doi:10.1136/jitc-2023-006920
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Merle P, Blanc JF, Edeline J, et al. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. Dig Liver Dis. 2023;55(4):464–470. doi:10.1016/j.dld.2023.01.161
   PubMedGoogle Scholar
• Lu J, Guo JH, Ji JS, et al. Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial. Int J Surg. 2023;109(5):1188–1198. doi:10.1097/JS9.0000000000000295
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Y, Wei Z, et al. Exploratory study of microparticle transcatheter arterial chemoembolization combined with resection for huge hepatocellular carcinoma. iLIVER. 2022;1(1):35–42. doi:10.1016/j.iliver.2022.01.001
   Google Scholar
• Fu J, Cao S, Song L, et al. Radiomics/Radiogenomics in hepatocellular carcinoma applications and challenges in interventional management. iLIVER. 2022;1(2):96–100 doi:10.1016/j.iliver.2022.07.001.
   Google Scholar
• Deng Z, Wang Y. Predictors of liver failure after transarterial chemoembolization in patients with spontaneously ruptured hepatocellular carcinoma: a retrospective study. J Interv Med. 2023;6(1):35–40. doi:10.1016/j.jimed.2022.10.003
   PubMedGoogle Scholar
• Yuan H, Lu H, Zeng J, Zhang Y, Shen L. Comparison of radiation doses between hepatic artery infusion chemotherapy and transarterial chemoembolization for liver cancer. J Interv Med. 2021;4(4):184–189. doi:10.1016/j.jimed.2021.08.004
   PubMedGoogle Scholar
• Yang XD, Kong FE, Qi L, et al. PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer. 2021;20(1):20. doi:10.1186/s12943-021-01315-9
   PubMed Web of Science ®Google Scholar
• Yousef EH, El-Magd NFA, El Gayar AM. Norcantharidin potentiates sorafenib antitumor activity in hepatocellular carcinoma rat model through inhibiting IL-6/STAT3 pathway. Transl Res. 2023;S1931–S5244(23):69–82.
   Google Scholar
• Ostwal V, Ramaswamy A, Gota V, et al. Phase I study evaluating dose de-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). Oncologist. 2022;27(3):165–e222. doi:10.1093/oncolo/oyab008
   PubMed Web of Science ®Google Scholar
• Zheng K, Zhu X, Fu S, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303(2):455–464. doi:10.1148/radiol.211545
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, Phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, Phase III Trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468–480. doi:10.1200/JCO.21.01963
   PubMed Web of Science ®Google Scholar
• Pereira H, Bouattour M, Dioguardi Burgio M, et al. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). Eur J Cancer. 2021;154:46–56. doi:10.1016/j.ejca.2021.05.032
   PubMed Web of Science ®Google Scholar
• Ioannidis J. Next-generation systematic reviews: prospective meta-analysis, individual-level data, networks and umbrella reviews. Br J Sports Med. 2017;51(20):1456–1458. doi:10.1136/bjsports-2017-097621
   PubMed Web of Science ®Google Scholar
• Shi X, Wallach JD. Umbrella reviews: a useful study design in need of standardization. BMJ. 2022;378. doi:10.1136/bmj.o1740
   PubMedGoogle Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi:10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. doi:10.1136/bmj.j4008
   PubMed Web of Science ®Google Scholar
• Bortolato B, Köhler CA, Evangelou E, et al. Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses. Bipolar Disord. 2017;19(2):84–96. doi:10.1111/bdi.12490
   PubMed Web of Science ®Google Scholar
• Dragioti E, Evangelou E, Larsson B, Gerdle B. Effectiveness of multidisciplinary programmes for clinical pain conditions: an umbrella review. J Rehabil Med. 2018;50(9):779–791. doi:10.2340/16501977-2377
   PubMed Web of Science ®Google Scholar
• He Y, Li X, Gasevic D, et al. Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials. Ann Intern Med. 2018;169(8):543–553. doi:10.7326/M18-0808
   PubMed Web of Science ®Google Scholar
• Kalliala I, Markozannes G, Gunter MJ, et al. Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ. 2017;359:j4511. doi:10.1136/bmj.j4511
   PubMedGoogle Scholar
• Veronese N, Solmi M, Caruso MG, et al. Dietary fiber and health outcomes: an umbrella review of systematic reviews and meta-analyses. Am J Clin Nutr. 2018;107(3):436–444. doi:10.1093/ajcn/nqx082
   PubMed Web of Science ®Google Scholar
• Li D, Pang Y, Xu L, Xu X. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: a meta-analysis. J BUON. 2021;26(4):1355–1364.
   PubMedGoogle Scholar
• Hu MD, Jia LH, Liu HB, Zhang KH, Guo GH. Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci. 2016;20(1):64–74.
   PubMed Web of Science ®Google Scholar
• Xie Y, Tian H, Xiang H. Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma? Tumori. 2021;107(4):292–303. doi:10.1177/0300891620945029
   PubMed Web of Science ®Google Scholar
• Cheng Z, He L, Guo Y, Song Y, Song S, Zhang L. The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. World J Surg Oncol. 2020;18(1):243. doi:10.1186/s12957-020-02017-0
   PubMed Web of Science ®Google Scholar
• Zeng J, Lv L, Mei ZC. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2016;40(6):688–697. doi:10.1016/j.clinre.2016.04.006
   PubMed Web of Science ®Google Scholar
• Zhang L, Hu P, Chen X, Bie P, Yang L-Y. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One. 2014;9(6):e100305. doi:10.1371/journal.pone.0100305
   PubMed Web of Science ®Google Scholar
• Li L, Zhao W, Wang M, et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2018;18(1):138. doi:10.1186/s12876-018-0849-0
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang K, Wang M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget. 2017;8(17):29416–29427. doi:10.18632/oncotarget.15075
   PubMedGoogle Scholar
• Jin PP, Shao SY, Wu WT, et al. Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis. Jpn J Clin Oncol. 2018;48(12):1058–1069. doi:10.1093/jjco/hyy138
   PubMed Web of Science ®Google Scholar
• Fu QH, Zhang Q, Bai XL, et al. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(8):1429–1440. doi:10.1007/s00432-014-1684-5
   PubMed Web of Science ®Google Scholar
• Yang M, Yuan JQ, Bai M, Han GH. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep. 2014;41(10):6575–6582. doi:10.1007/s11033-014-3541-7
   PubMed Web of Science ®Google Scholar
• Cai R, Song R, Pang P, et al. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2017;17(1):714. doi:10.1186/s12885-017-3707-5
   PubMedGoogle Scholar
• Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol. 2011;29(30):3949–3952. doi:10.1200/JCO.2011.37.9651
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Bergamini C, Leoni I, Rizzardi N, et al. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma. J Exp Clin Cancer Res. 2023;42(1):145. doi:10.1186/s13046-023-02718-w
   PubMed Web of Science ®Google Scholar
• Lien RY, Tung HH, Wu SL, Hu SH, Lu LC, Lu SF. Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: a randomised experiment study. Cancer Rep. 2022;5(7):e1532. doi:10.1002/cnr2.1532
   Google Scholar
• Chen LT, Martinelli E, Cheng AL, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334–351. doi:10.1016/j.annonc.2019.12.001
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):871–873. doi:10.1093/annonc/mdy510
   PubMed Web of Science ®Google Scholar
• Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38(36):4317–4345. doi:10.1200/JCO.20.02672
   PubMed Web of Science ®Google Scholar
• Park JW, Kim YJ, Kim DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol. 2019;70(4):684–691. doi:10.1016/j.jhep.2018.11.029
   PubMed Web of Science ®Google Scholar
• Shuen TWH, Alunni-Fabbroni M, Öcal E, et al. Extracellular vesicles may predict response to radioembolization and sorafenib treatment in advanced hepatocellular carcinoma: an exploratory analysis from the SORAMIC Trial. Clin Cancer Res. 2022;28(17):3890–3901. doi:10.1158/1078-0432.CCR-22-0569
   PubMed Web of Science ®Google Scholar
• Chen A, Li S, Yao Z, et al. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2021;36(2):302–310. doi:10.1111/jgh.15180
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang WJ, Guan S, et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol. 2013;24(7):1786–1792. doi:10.1093/annonc/mdt072
   PubMed Web of Science ®Google Scholar
• Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136(6):1458–1467. doi:10.1002/ijc.29126
   PubMed Web of Science ®Google Scholar
• Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF. Open-label single-arm Phase II trial of sorafenib therapy with drug-eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Clin Results Radiol. 2015;277(2):594–603.
   Google Scholar
• Geschwind JF, Kudo M, Marrero JA, et al. TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice final analysis of GIDEON. Radiology. 2016;279(2):630–640.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68(5):609–617. doi:10.1111/ijcp.12352
   PubMed Web of Science ®Google Scholar